

FOR IMMEDIATE RELEASE

Contact: Barbara Kowalski
FischerHealth
310-577-7870 x171
bkowalski@fischerhealth.com

OPHTHONIX CEO to BECOME CHAIRMAN

Founder Dr. Andreas Dreher to pursue new business venture

SAN DIEGO (July 31, 2007)— Stephen Osbaldeston, chief executive of Ophthonix, will assume the role of chairman of the board for the company. Nearly seven years after founding Ophthonix, Andreas Dreher, Ph.D. has decided to leave Ophthonix where his most recent positions included chairman of the board and chief technology officer, the company announced today.

Dreher will be leading another start-up company in the ophthalmic field, but will continue to assist the company in its strategic and technological development as a consultant.

Dreher founded Ophthonix in December 2000 with technology originally created during the U.S. government's Strategic Defense Initiative (SDI), or "Star Wars" program, and an understanding that these technologies had the potential to revolutionize vision correction.

"I am extremely grateful to Andreas for bringing his vision to life with Ophthonix. He had the foresight to bring distinct technologies together and create the iZon eyeglass lenses that enable people to see like never before," said Stephen Osbaldeston, chief executive of Ophthonix.

"My passion lies in the early development of work transforming basic concepts into viable businesses," said Dreher. "Now that Ophthonix has transitioned from a research and development company to a marketing and sales-oriented enterprise, I believe my vision for this company has been realized and I am ready for the next challenge."

The company plans to seek a replacement to fill the chief technology officer position.

Ophthonix's Z-View[®] Aberrometer employs proprietary wavefront technology to map a patient's eye for higher order aberrations, or irregularities, which can cause vision problems such as distortions, glare, halos and starbursts around lights.

The company's patented iZon[®] High Resolution Lenses are manufactured based on this map or iPrint[™], which is unique to each person's eye much like a fingerprint. As a result, iZon Lenses provide patients with improved contrast acuity, improved night vision, generally sharper vision and the ability to see color with greater richness and intensity—much like the difference between regular and high definition television.

About Ophthonix

Ophthonix, Inc., a San Diego-based vision-correction company, manufactures and markets the patented Z-View Aberrometer and iZon High Resolution Spectacle Lenses for superior vision assessment and correction.

Ophthonix is venture funded by the following blue chip firms: DAG Ventures; Enterprise Partners; Gund Investment Corporation; InterWest Partners; Kleiner Perkins Caufield & Byer; Palo Alto Investors; Trex Enterprises; Wasatch Advisors and its affiliate, Cross Creek Capital. For more information, contact Ophthonix at (858) 869-2100 or visit www.izonlens.com.